Patents by Inventor Takahiro Sugimoto

Takahiro Sugimoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10899752
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: January 26, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Masataka Murakami, Jinichi Yonemori, Takuto Kojima
  • Patent number: 10898737
    Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: January 26, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko Fujimoto, Kentaro Rikimaru, Hiromichi Sugimoto, Takahiro Matsumoto
  • Publication number: 20210009572
    Abstract: The present invention provides a compound having a cholinergic muscarinic Ml receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: September 30, 2020
    Publication date: January 14, 2021
    Inventors: Masami YAMADA, Shinkichi SUZUKI, Takahiro SUGIMOTO, Minoru NAKAMURA, Hiroki SAKAMOTO, Makoto KAMATA
  • Patent number: 10865200
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: December 15, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masami Yamada, Shinkichi Suzuki, Takahiro Sugimoto, Minoru Nakamura, Hiroki Sakamoto, Makoto Kamata
  • Publication number: 20200385346
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: August 2, 2018
    Publication date: December 10, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko FUJIMOTO, Kentaro RIKIMARU, Koichiro FUKUDA, Hiromichi SUGIMOTO, Takahiro MATSUMOTO, Yuichi KAJITA, Satoshi MIKAMI, Yuhei MIYANOHANA, Tatsuki KOIKE, Masaki DAINI, Masaki OGINO, Kohei TAKEUCHI, Tohru MIYAZAKI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
  • Publication number: 20200321781
    Abstract: A method includes acquiring weather information relating to at least one of physical quantities including insolation, cloudiness, and humidity; performing a rating scale assessment of the weather information based on a predetermined threshold value; predicting an electrical output of a solar generator; performing a rating scale assessment of the electrical output of the solar generator based on a standard electrical output of the solar generator; and generating information indicating an assessment value obtained in the performing of the rating scale assessment of the weather information, and an assessment value obtained in the performing of the rating scale assessment of the electrical output.
    Type: Application
    Filed: May 16, 2017
    Publication date: October 8, 2020
    Applicants: Panasonic Intellectual Property Management Co., Ltd., Panasonic Intellectual Property Management Co., Ltd.
    Inventors: Takahiro SUGIMOTO, Kotaro SAKATA, Kazuya ITO, Takaaki YOSHIHARA, Takashi TORII
  • Publication number: 20200247747
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: January 30, 2020
    Publication date: August 6, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yasushi Hattori, Yuhei Miyanohana, Yuichi Kajita, Tatsuki Koike, Yasutaka Hoashi, Norihito Tokunaga, Alexander Martin Pawliczek, Tsuneo Oda, Tohru Miyazaki, Yoshiteru Ito, Kohei Takeuchi, Keisuke Imamura, Takahiro Sugimoto
  • Publication number: 20200232810
    Abstract: Driving assistance systems, methods, and programs accept an inputted planned travel route from the route guidance system, provide driving assistance of the vehicle on the planned travel route, based on driving assistance map data, and obtain, when versions of the route guidance map data and the driving assistance map data do not match each other, the driving assistance map data whose version matches the version of the route guidance map data from a map provider. Route guidance systems search for a planned travel route based on route guidance map data, provide guidance on the planned travel route, output the planned travel route to the driving assistance system, and obtain, when versions of the route guidance map data and the driving assistance map data do not match each other, the route guidance map data whose version matches the version of the driving assistance map data from a map provider.
    Type: Application
    Filed: May 28, 2018
    Publication date: July 23, 2020
    Applicants: AISIN AW CO., LTD., TOYOTA JIDOSHA KABUSHIKI KAISHA
    Inventors: Sadahiro KOSHIBA, Kazuteru MAEKAWA, Seiji TAKAHATA, Takahiro YAMAGUCHI, Shingo KINASHI, Yuji SATO, Hironobu SUGIMOTO, Xin JIN, Hiroaki SAKAKIBARA
  • Publication number: 20200226048
    Abstract: A monitoring system includes storage, and one or more processors. The storage stores at least one of first output data that is obtained from a learning model, or first statistical information that is obtained from the first output data. The processors calculate a degree of abnormality indicating a degree of change in statistical information of second output data with respect to the first statistical information, or a degree of change in the statistical information of the second output data with respect to second statistical information. The processors determine whether or not there is occurrence of an abnormality in the learning model, on the basis of the degree of abnormality. The processors output information indicating occurrence of the abnormality, in a case where occurrence of the abnormality is determined.
    Type: Application
    Filed: August 16, 2019
    Publication date: July 16, 2020
    Applicants: Kabushiki Kaisha Toshiba, Toshiba Memory Corporation
    Inventors: Mitsuhiro KIMURA, Takahiro Takimoto, Akira Sugimoto, Kosuke Haruki, Masahiro Ozawa
  • Publication number: 20200207715
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: March 6, 2020
    Publication date: July 2, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Yuhei MIYANOHANA, Tatsuki KOIKE, Kohei TAKEUCHI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tohru MIYAZAKI, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
  • Publication number: 20200207734
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: August 2, 2018
    Publication date: July 2, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi KAJITA, Satoshi MIKAMI, Yuhei MIYANOHANA, Tatsuki KOIKE, Masaki DAINI, Norio OYABU, Masaki OGINO, Kohei TAKEUCHI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tohru MIYAZAKI, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
  • Publication number: 20200202954
    Abstract: According to one embodiment, a semiconductor memory device includes: a memory cell array; a conversion circuit; a data bus; a first buffer and a second buffer; and a third buffer. The data bus includes a first wiring part extending along a first direction. The first buffer and the second buffer are separate from each other. The first to third buffers are at different positions along the first direction.
    Type: Application
    Filed: September 5, 2019
    Publication date: June 25, 2020
    Applicant: TOSHIBA MEMORY CORPORATION
    Inventors: Hiromi NORO, Yusuke OCHI, Takahiro SUGIMOTO, Naoaki KANAGAWA
  • Publication number: 20200173793
    Abstract: A driving assistance systems, methods, and programs are capable of communicating with a route guidance system that searches for a planned travel route of a vehicle and provides guidance on the planned travel route. The systems, methods, and programs accept, as input, the planned travel route from the route guidance system as a route for driving assistance and provide driving assistance of the vehicle on the route for driving assistance. The systems, methods, and programs accept, as input, when the planned travel route whose guidance is provided by the route guidance system no longer matches the route for driving assistance, the planned travel route from the route guidance system.
    Type: Application
    Filed: May 28, 2018
    Publication date: June 4, 2020
    Applicants: AISIN AW CO., LTD., TOYOTA JIDOSHA KABUSHIKI KAISHA
    Inventors: Sadahiro KOSHIBA, Kazuteru MAEKAWA, Seiji TAKAHATA, Takahiro YAMAGUCHI, Shingo KINASHI, Yuji SATO, Hironobu SUGIMOTO, Xin JIN, Hiroaki SAKAKIBARA
  • Publication number: 20200127081
    Abstract: A semiconductor device includes a first semiconductor layer that is an electrically-conductive polycrystalline semiconductor layer and a second semiconductor layer on the first semiconductor layer. The second semiconductor layer is an electrically-conductive polycrystalline semiconductor layer having a smaller average grain size than the first semiconductor layer. A plurality of electrode layers are stacked on the second semiconductor layer at intervals in a first direction. A third semiconductor layer extends in the first direction through the first semiconductor layer, the second semiconductor layer, and each of the electrode layers and contacts the second semiconductor layer. A charge storage layer is between the plurality of electrode layers and the third semiconductor layer.
    Type: Application
    Filed: August 23, 2019
    Publication date: April 23, 2020
    Inventors: Takashi ISHIDA, Takahiro SUGIMOTO, Hiroshi KANNO, Tatsuya OKAMOTO
  • Publication number: 20200115399
    Abstract: Provided is a substituted piperidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as a prophylactic or therapeutic agent for narcolepsy.
    Type: Application
    Filed: December 13, 2019
    Publication date: April 16, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko FUJIMOTO, Kentaro RIKIMARU, Koichiro FUKUDA, Hiromichi SUGIMOTO, Takahiro MATSUMOTO, Norihito TOKUNAGA, Mariko HIROZANE
  • Publication number: 20200116444
    Abstract: Mg and Bi are contained in each of a first fillet in a first braze joining portion in which a tube and a fin join, a second fillet in a second braze joining portion in which the tube and a header plate join, and a third fillet in a third braze joining portion in which the header plate and a tank body join. A concentration of Mg of each of the first to third fillets is from 0.2% or more to 2.0% or less by mass. When the tube includes a brazing material layer, a concentration of Mg of the tube at its plate thickness center is from 0.1% or more to 1.0% or less by mass. When the fin includes a brazing material layer, a concentration of Mg of the fin at its plate thickness center is from 0.2% or more to 1.0% or less by mass.
    Type: Application
    Filed: October 8, 2019
    Publication date: April 16, 2020
    Inventors: Takahiro SHINODA, Shogo YAMADA, Nobuhiro HONMA, Naoki SUGIMOTO, Taketoshi TOYAMA
  • Patent number: 10584097
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: March 10, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike, Kohei Takeuchi, Yoshiteru Ito, Norihito Tokunaga, Takahiro Sugimoto, Tohru Miyazaki, Tsuneo Oda, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura
  • Patent number: 10548899
    Abstract: The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: February 4, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Masaki Ogino, Eiji Kimura, Masataka Murakami, Takuto Kojima, Jinichi Yonemori
  • Publication number: 20200030473
    Abstract: A light introduction device (3) has an inner cavity allowing passage of at least one of a substance introduced into a human body or a substance discharged from the human body. Light is introduced from part of an outer surface of a section, which is arranged outside the human body, of a catheter (2) as a medical conduit having a light-permeable thick portion.
    Type: Application
    Filed: January 12, 2018
    Publication date: January 30, 2020
    Inventors: Koichi SUGIMOTO, Takahiro NAKAMA, Hideki ASANO
  • Publication number: 20200017444
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: September 20, 2019
    Publication date: January 16, 2020
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi KAJITA, Satoshi MIKAMI, Yuhei MIYANOHANA, Tatsuki KOIKE, Masaki DAINI, Norio OYABU, Masaki OGINO, Kohei TAKEUCHI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tohru MIYAZAKI, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA